Wire · opportunities
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
Lebrikizumab significantly improved clearance, itch, and pain in hand and foot atopic dermatitis patients in a phase 3b trial, showing 53% clear or almost clear compared to 27% on placebo at 16 weeks. The results were presented at the European Academy of Dermatology and Venereology Congress and support a potential FDA label update for this indication.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
Your medtech product roadmap must factor in symptom relief measures beyond skin clearance for hand and foot dermatitis. Lilly’s success with lebrikizumab shows patient satisfaction hinges on pain and itch control as much as visible improvement.
◆ Coverage
1 source · 1 Oct 2026
◆ Related on Wire
◆ Topics